COMMUNIQUÉS West-GlobeNewswire

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
05/02/2024
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 [...]
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
05/02/2024
Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of [...]
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company
05/02/2024
Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region TORONTO, Feb. 05, 2024 ( [...]
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
05/02/2024
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and [...]
One World Products Confirms That Its Colombian Cannabis Operations are Unaffected by Recent Regulatory Developments in Colombia
05/02/2024
Recent Agreements Executed with Smokiez Edibles and the Marley Family’s Kx Family Care Are Expected to Ramp Operations in Early 2024 LAS VEGAS, NV , Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World [...]
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
05/02/2024
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- [...]
Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
05/02/2024
Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo [...]
ALK’s 2030 CO2 reduction targets have been approved by SBTi
05/02/2024
ALK’s near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative. Today, ALK announces that its near-term carbon reduction targets have been [...]
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis
05/02/2024
First-in-class, peripheral-acting serotonin receptor antagonist being developed as an anti-fibrotic treatment for systemic sclerosis LUND, Sweden, Feb. 05, 2024 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech [...]
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
05/02/2024
Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses Paris, February 5, 2024 . Sanofi today launches ‘Cancer & Work: [...]
Communiqué de presse : Entraide, conditions de travail flexibles, salaire pendant un an : Sanofi lance un programme mondial pour les employés touchés par un cancer ou une maladie grave
05/02/2024
Entraide, conditions de travail flexibles, salaire pendant un an : Sanofi lance un programme mondial pour les employés touchés par un cancer ou une maladie grave Paris, le 5 février 2024 . Sanofi annonce aujourd’hui le [...]
Valneva Announces Sale of Priority Review Voucher for $103 Million
05/02/2024
Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug [...]
Valneva annonce la vente de son bon de revue prioritaire (PRV) pour 103 millions de dollars
05/02/2024
Saint-Herblain (France), 5 février 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui la vente pour 103 millions de dollars (95 millions d’euros) du bon de [...]
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
05/02/2024
Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall survival The designation was [...]
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
04/02/2024
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced [...]
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
03/02/2024
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12 months) were [...]
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
03/02/2024
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901 Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were [...]
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
03/02/2024
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Alira Health publie un rapport mondial sur la chirurgie robot-assistée (ou « RAS » pour Robotic-Assisted Surgery) en orthopédie
02/02/2024
L’étude révèle que le marché devrait progresser au rythme de 10 % par an au cours des cinq prochaines années, pour dépasser les 2,6 millions d’interventions dans l’UE, au Royaume-Uni et aux États-Unis FRAMINGHAM, État [...]

Pages